X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Tom Wilbur

Tom Wilbur is Director of Public Affairs at PhRMA focusing on federal advocacy priorities including Medicare and intellectual property. Prior to joining PhRMA, Tom worked in politics and on Capitol Hill, most recently responsible for communications and strategy for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom is a proud Michigander and outside of the office enjoys reading, running, hiking, golfing, live music, and spending time with family and friends.

Recent Posts

The latest: What they are saying: Importance of intellectual property protections to combat COVID-19

By Tom Wilbur  |    July 2, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19

By Tom Wilbur  |    June 5, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new treatments and cures for patients. Strong IP protections are...   Read More

What they are saying: Intellectual property protections are critical as we work to defeat COVID-19

By Tom Wilbur  |    May 4, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new breakthrough treatments and cures for patients. Strong IP...   Read More

New infographic: How we are fighting COVID-19

By Tom Wilbur  |    April 8, 2020
America’s biopharmaceutical companies have joined forces to fight COVID-19. Armed with experience garnered from previous outbreaks and a vast storehouse of knowledge about infectious diseases like...   Read More

PhRMA submits comments on CMS’s Part D specialty tier proposal

By Tom Wilbur  |    April 7, 2020
Yesterday, PhRMA submitted comments on a Centers for Medicare & Medicaid Services (CMS) proposed rule on policy and technical changes to Medicare Part D and Medicare Advantage.   Read More

IP Explained: Four key takeaways from new Bayh-Dole white paper

By Tom Wilbur  |    February 19, 2020
2020 marks the 40th anniversary of the Bayh-Dole Act being signed into law. The Bayh-Dole Act laid the foundation for effective technology transfer that modernized the U.S. economy, set a global...   Read More

What you need to know about H.R. 3

By Tom Wilbur  |    December 12, 2019
Speaker of the House Nancy Pelosi’s drug pricing proposal, H.R. 3, which is being voted on in the U.S. House of Representatives today, is unprecedented in size and scope. It dramatically expands...   Read More

Pelosi’s radical plan would leave patients with sickle cell disease behind

By Tom Wilbur  |    November 14, 2019
Sickle cell disease (SCD) is the most commonly inherited genetic blood disorder, affecting nearly 100,000 children and adults in the United States. Three million Americans carry the sickle cell...   Read More

Pelosi’s radical plan would leave patients with rare pediatric diseases behind

By Tom Wilbur  |    November 7, 2019
There are about 7,000 rare diseases and half of these affect children. According to the National Institutes of Health (NIH), 30 million Americans, or 10 percent of the population, have one of the...   Read More

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy

By Tom Wilbur  |    November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

Subscribe to Email Updates